↓ Skip to main content

Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation

Overview of attention for article published in Acta Diabetologica, April 2018
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
39 Mendeley
Title
Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation
Published in
Acta Diabetologica, April 2018
DOI 10.1007/s00592-018-1141-z
Pubmed ID
Authors

Stefano Benedini, Federica Ermetici, Silvia Briganti, Roberto Codella, Ileana Terruzzi, Paola Maffi, Rossana Caldara, Antonio Secchi, Rita Nano, Lorenzo Piemonti, Rodolfo Alejandro, Camillo Ricordi, Livio Luzi

Abstract

The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues. This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM). Forty-one T1DM patients were studied. Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2). Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function. A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity. We found a significant reduction in DIR after rapamycin pre-treatment (- 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx. DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (- 37 ± 15 vs. - 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006). Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: - 2.1 ± 1.4%, p = 0.002), while fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups. Hepatic glucose production decreased after rapamycin pre-treatment (- 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (- 1.6 ± 0.6 mg/kg/min, p = 0.015), while no changes in peripheral glucose disposal were observed. Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity. This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance. Clinicaltrials.gov NCT01060605; NCT00014911.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 21%
Student > Bachelor 5 13%
Student > Ph. D. Student 4 10%
Student > Master 4 10%
Student > Doctoral Student 3 8%
Other 5 13%
Unknown 10 26%
Readers by discipline Count As %
Medicine and Dentistry 11 28%
Nursing and Health Professions 3 8%
Immunology and Microbiology 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Neuroscience 2 5%
Other 5 13%
Unknown 14 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2020.
All research outputs
#18,603,172
of 23,043,346 outputs
Outputs from Acta Diabetologica
#658
of 931 outputs
Outputs of similar age
#254,524
of 327,997 outputs
Outputs of similar age from Acta Diabetologica
#13
of 22 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 931 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,997 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.